Carisma updates CT-0508 interim data; merger with Sesen expected to close in 1-2 months

Carisma Therapeutics Inc.

Updated interim data from CT-0508 Study 101 supports safety profile and tumor infiltration.
Carisma outlines six pre-clinical and clinical milestones expected in 2023.
Merger with Sesen expected to close in 1-2 months, subject to stockholder approval.

item 8.01 item 9.01

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001485003-22-000164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.